The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Gustav Smith

Associate professor

Default user image.

β-Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study.

Author

  • Pontus Andell
  • David Erlinge
  • Gustav Smith
  • Johan Sundström
  • Bertil Lindahl
  • Stefan James
  • Sasha Koul

Summary, in English

Patients with myocardial infarction (MI) and concomitant chronic obstructive pulmonary disease (COPD) constitute a high-risk group with increased mortality. β-Blocker therapy has been shown to reduce mortality, prevent arrhythmias, and delay heart failure development after an MI in broad populations. However, the effect of β-blockers in COPD patients is less well established and they may also be less treated due to fear of adverse reactions. We investigated β-blocker prescription at discharge in patients with COPD after MI.

Department/s

  • Cardiology
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2015

Language

English

Pages

001611-001611

Publication/Series

Journal of the American Heart Association

Volume

4

Issue

4

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

ISBN/ISSN/Other

  • ISSN: 2047-9980